Abstract
Therapy preferences of patients with cancer
Journal of clinical oncology, Vol.41(16_suppl), pp.e24205-e24205
06/01/2023
DOI: 10.1200/JCO.2023.41.16_suppl.e24205
Abstract
e24205 Background: Clear understanding of patient (pt) preferences is crucial for creating a treatment (tx) plan that aligns with pt's goals and expectations. We developed "Therapy Preference Scale" (TPS), a self-reported questionnaire, to measure tx preferences of pts with cancer. TPS includes 30 questions: 19 questions on pt preferences on safety, efficacy, and other aspects of therapy (on scale of 0-10), 8 questions on importance of different aspects of tx (on 4-item Likert scale with choices of 'strongly disagree,' 'disagree,' 'agree,' and 'strongly agree.'), and 3 questions on intent of therapy, expenses, and life expectancy gain. This report presents results of the 8 questions rated on the 4-item Likert scale from a prospective study using TPS. Methods: 300 pts > 18 yrs with a cancer diagnosis completed TPS. We divided pts into 4 groups: Male < 60 yrs (M < 60), Male ≥60 yrs (M ≥60), Female < 60 yrs (F < 60), and Female ≥60 yrs (F ≥60). We compared responses between M < 60 and M≥60 and between F < 60 and F≥60. The responses were categorized into 2 groups: "disagree" (combining "strongly disagree" and "disagree") and "agree" (combining "strongly agree" and "agree"). Results: Median age was 61 yrs (range 19-89). 62% had solid tumors. 57% indicated cure as their tx goal versus gain in life expectancy without cure (35%) or symptom relief (8%). 4 groups were 20% M < 60, 32% M ≥60, 19% F < 60, and 29% F ≥60. M < 60 were more likely to accept tx with side effects and financial burden, while M ≥60 prioritized avoiding poor quality of life (QoL). F < 60 were more likely to undergo tx causing significant pain, while F ≥60 would avoid permanent cognitive impairment. Table 1 shows percentage of pts who agreed with the 8 questions. Conclusions: Despite similar preferences for a cure, age and gender play role in prioritizing tx options, including those with potential side effects such as life-threatening infection, poor QoL, financial burden, severe pain, and permanent cognitive impairment. TPS can improve the precision medicine approach and aid in choosing the right tx for each pt. [Table: see text]
Details
- Title: Subtitle
- Therapy preferences of patients with cancer
- Creators
- Prajwal Dhakal - University of IowaChristopher S. Wichman - University of Nebraska Medical CenterBunny J. Pozehl - University of Nebraska Medical CenterRadowan Elnair - University of Nebraska Medical CenterAmulya Yellala - University of Nebraska Medical CenterKalika Mahato - University of Nebraska Medical CenterVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.41(16_suppl), pp.e24205-e24205
- DOI
- 10.1200/JCO.2023.41.16_suppl.e24205
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: None.
- Language
- English
- Date published
- 06/01/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984442026802771
Metrics
1 Record Views